Veldhuis. Johannes D JD; Keenan. Daniel M DM; Bailey. Joy N JN; Adeniji. Adebordurin M AM; Miles. Jo...
In men whose sex hormones are low, older age and more belly fat make the growth‑hormone‑boosting peptide GHRP‑2 work less well, while higher natural IGF‑I levels make it work better. This means the same dose won’t give the same GH spike in everyone.
Veldhuis. Johannes D JD; Bowers. Cyril Y CY
Although stimulatory (feedforward) and inhibitory (feedback) dynamics jointly control neurohormone secretion, the factors that supervise feedback restraint are poorly understood. To parse the regulation of growth hormone (GH) escape from negative feedback, 25 healthy men and women were studied eight times each during an experimental GH feedback clamp. The clamp comprised combined bolus infusion of GH or saline and continuous stimulation by saline GH-releasing hormone (GHRH), GHRP-2, or both peptides after randomly ordered supplementation with placebo (both sexes) vs. E(2) (estrogen; women) and T (testosterone; men). Endpoints were GH pulsatility and entropy (a model-free measure of feedback quenching). Gender determined recovery of pulsatile GH secretion from negative feedback in all four secretagog regimens (0.003 ≤ P ≤ 0.017 for women>men). Peptidyl secretagog controlled the mass, number, and duration of feedback-inhibited GH secretory bursts (each, P < 0.001). E(2)/T administration potentiated both pulsatile (P = 0.006) and entropic (P < 0.001) modes of GH recovery. IGF-I positively predicted the escape of GH secretory burst number and mode (P = 0.022), whereas body mass index negatively forecast GH secretory burst number and mass (P = 0.005). The composite of gender, body mass index, E(2), IGF-I, and peptidyl secretagog strongly regulates the escape of pulsatile and entropic GH secretion from autonegative feedback. The ensemble factors identified in this preclinical investigation enlarge the dynamic model of GH control in humans.
Celichowska. Magdalena M; Miedziaszczyk. Miłosz M; Lacka. Katarzyna K
Cachexia is a state of increased metabolism associated with high morbidity and mortality. Dysregulation of cytokines and hormone activity causes reduced protein synthesis and excessive protein breakdown. various treatments are available, depending on the primary disease and the patient's state. Besides pharmacological treatment, crucial is nutritional support as well as increasing physical activity. The main purpose of pharmacological treatment is to diminish inflammation, improve appetite and decrease muscle wasting. Therefore a lot of medications aim at proinflammatory cytokines such as Interferon-α or Tumor Necrosis Factor-β, but because of the complicated mechanism of cachexia, the range of targets is very wide. in cachexia treatment, use of corticosteroids is common, which improve appetite, diminish inflammation, inhibit prostaglandin metabolism, Interleukin-1 activity. They can also decrease protein synthesis and increase protein degradation, which can be prevented by resveratrol. Estrogen analogs, progesterone analogs, testosterone analogs, Selective Androgen Receptor Modulators (SARM), Angiotensin-Converting-Enzyme Inhibitors (ACEI), Nonsteroidal anti-inflammatory drugs (NSAIDs), thalidomide, melatonin, Growth Hormone Releasing Peptide-2 (GHRP-2) may play important role in wasting syndrome treatment as well. However, for the usage of some of them, evidence-based recommendations are not available. This review highlights current therapeutic options for cachexia with a specific focus on steroid therapy.
Norman. Catalina C; Rollene. Nanette L NL; Erickson. Dana D; Miles. John M JM; Bowers. Cyril Y CY; V...
Error: Malformed JSON response.
Naito. Kumiko K; Suzuki. Sawako S; Ohwada. Chikako C; Ishiwata. Kazuki K; Ruike. Yutaro Y; Ishida. A...
The study describes a rare type of blood‑vessel‑based lymphoma that can affect the pituitary gland, causing hormone problems that can improve after chemotherapy. It does not discuss the peptide GHRP‑2 or any health‑boosting protocol.
Okauchi. Seizo S; Tatsumi. Fuminori F; Kan. Yuki Y; Horiya. Megumi M; Mizoguchi. Akiko A; Fushimi. Y...
A 65‑year‑old man had unexplained stomach discomfort and fatigue, which turned out to be caused by a rare, isolated lack of ACTH hormone. Doctors diagnosed it using hormone‑release tests, including a GHRP‑2 test, and treated him with hydrocortisone, which quickly improved his symptoms.
Timms. Mark M; Hall. Nikki N; Levina. Vita V; Vine. John J; Steel. Rohan R
The paper describes a lab test that can spot a group of synthetic growth‑hormone‑releasing peptides (including GHRP‑2) in horse or human urine. It focuses on how to extract and chemically modify the peptides so they show up better on a mass‑spectrometer, and it proves the test works in rats.
Kageyama. Kazunori K; Sakihara. Satoru S; Kameda. Wataru W; Sugiyama. Aya A; Takayasu. Shinobu S; Te...
The study looked at whether giving the peptide GHRP‑2 can help diagnose a rare type of pituitary tumor that makes too much thyroid‑stimulating hormone. It found that only a few patients showed a big rise in hormone levels after the peptide, so it’s not a reliable test for most cases.
Roelfsema. F F; Biermasz. N R NR; Veldman. R G RG; Veldhuis. J D JD; Frölich. M M; Stokvis-Bran...
Error: Malformed JSON response.
Roh. S G SG; Hirota. M M; He. M L ML; Matsunaga. N N; Hidaka. S S; Hidari. H H
Error: Timeout.